(7R)-7-[(phenylacetyl)amino]-3-trifluoromethanesulfonyloxy-3-cephem-4-carboxylate, 4-methoxybenzyl ester | 123054-30-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酰胺类
• 英文名称: (7R)-7-[(phenylacetyl)amino]-3-trifluoromethanesulfonyloxy-3-cephem-4-carboxylate, 4-methoxybenzyl ester
• 英文别名: 3-Trifluoromethylsulfonyloxy-Δ³-cephem；p-methoxybenzyl 7β-phenylacetylamino-3-trifluoromethylsulfonyloxy-3-cephem-4-carboxylate；8-oxo-7-phenylacetylamino-3-trifluoromethanesulfonyloxy-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 4-methoxybenzyl ester；p-methoxybenzyl (6R,7R)-7-phenylacetamido-3-(trifluoromethylsulphonyloxy)ceph-3-em-4-carboxylate；4-methoxybenzyl (6R,7R)-7-phenylacetamido-3-trifluoromethanesulphonyloxyceph-3-em-4-carboxylate；(4-methoxyphenyl)methyl (6R,7R)-8-oxo-7-[(2-phenylacetyl)amino]-3-(trifluoromethylsulfonyloxy)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
• CAS: 123054-30-8
• 化学式: C₂₄H₂₁F₃N₂O₈S₂
• 分子量: 586.567
• InChiKey: RTUUHJGWBNCWAO-DENIHFKCSA-N

物化性质

• 沸点：
  775.9±60.0 °C(Predicted)
• 密度：
  1.57±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  39
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  162
• 氢给体数：
  1
• 氢受体数：
  12

反应信息

• 作为反应物：
  描述：

  (7R)-7-[(phenylacetyl)amino]-3-trifluoromethanesulfonyloxy-3-cephem-4-carboxylate, 4-methoxybenzyl ester 在 吡啶 、 N,O-双三甲硅基乙酰胺 、 三(2-呋喃基)膦 、 五氯化磷 、 zinc(II) chloride 、 bis(dibenzylideneacetone)-palladium⁽⁰⁾ 作用下， 以 二氯甲烷 为溶剂， 反应 8.58h， 生成 (4-methoxyphenyl)methyl (6R,7R)-3-[(1E)-buta-1,3-dienyl]-7-[[(2Z)-2-(2-methoxypropan-2-yloxyimino)-2-[5-[(2-methylpropan-2-yl)oxycarbonylamino]-1,2,4-thiadiazol-3-yl]acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
  参考文献：
  名称：

  Structure-activity Relationships of Cephalosporins Having a (Dimethylisoxazolidinio)vinyl Moiety at Their 3-Position.

  摘要：

  合成了一系列在其3位具有（亚甲基异噁唑啉）乙烯基基团的头孢菌素，以研究其结构-活性关系。关于烯烃几何构型，（E）-乙烯基化合物在体外活性上比（Z）-化合物表现出更高的活性。关于C-7取代基，用5-氨基-1, 2, 4-噻二唑替代2-氨基噻唑可增加抗假单胞菌活性。此外，还展示了C-3取代基的绝对构型的确定。在所合成的化合物中，我们选择了7β-[(Z)-2-(5-氨基-1, 2, 4-噻二唑-3-基)-2-(氟甲氧基亚胺)乙酰氨基]-3-[(E)-2-((S)-2, 2-二甲基-5-异噁唑啉)乙烯]-3-头孢烯-4-羧酸酯（YM-40220），该化合物在体外表现出良好的平衡活性，对金黄色葡萄球菌Smith具有优异的体内疗效，作为进一步开发的候选药物。

  DOI：

  10.7164/antibiotics.49.1162
• 作为产物：
  描述：

  (4-methoxyphenyl)methyl (E)-2-[(2R,3R)-2-(benzenesulfonylsulfanyl)-4-oxo-3-[(2-phenylacetyl)amino]azetidin-1-yl]-4-chloro-3-hydroxybut-2-enoate 在 lead(II) bromide 、 三乙胺 、 氢化铝 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.1h， 生成 (7R)-7-[(phenylacetyl)amino]-3-trifluoromethanesulfonyloxy-3-cephem-4-carboxylate, 4-methoxybenzyl ester
  参考文献：
  名称：

  Synthesis of 2-exo-Methylenepenam and 3-Chloro-Δ³-cephem through a Sequential Reductive 1,2-Elimination/S−S Bond Fission or Chloride Ion-Addition/Cyclization of 3,4-Disubstituted 2-Butenoates in Metal Salt/Metal Combinations

  摘要：

  Synthesis of 2-exo-methylenepenam 1 through a sequential reductive 1,2-elimination/S-S bond fission/cyclization of 6 was performed by treatment with a PbBr2/Al (or a BiCl3/Al) combination in DMF, while that of 3-chloro-Delta(3)-cephem 2 through reductive 1,2-elimination/chloride ion-addition/cyclization was attained by use of an AlCl3/Al combination in N-methylpyrrolidone (NMP). The selective transformation of 6 to the allenecarboxylate 3 was also achieved by treatment with an AlBr3/Al combination in NMP. Cyclic voltammograms of 3,4-disubstituted 2-[2-oxo-3-(phenylacetamido)-4-[(phenylsulfonyl)thio]azetidin-1-yl]-2-butenoates (6) exhibit two irreversible reduction peaks responsible for reductive 1,2-elimination of the 3,4-disubstituted 2-butenoate moiety (at less negative potential) and for reductive S-S bond fission of the (phenylsulfonyl)thio moiety, suggesting that the reductive 1,2-elimination of 6 leading to allenecarboxylate 3 would occur prior to the reductive S-S bond cleavage.

  DOI：

  10.1021/jo970051n

文献信息

• Synthesis of cephalosporin derivatives utilizing the cephem triflate. 1. introduction of 3-position substituents via a cycloaddition-fragmentation route
  作者：Han-Young Kang、Sang Hak Lee、Kyung Il Choi、Hun Yeong Koh

  DOI：10.1016/0040-4039(96)01714-5

  日期：1996.10

  An efficient synthetic route for cephalosporin derivatives with various substituents at the 3-position has been developed. It involves cycloaddition with silyl enol ethers or silylketene acetals followedby fragmentation utilizing the 3-cephem triflate 1 as a starting material.

  已经开发了在3-位具有各种取代基的头孢菌素衍生物的有效合成途径。它涉及与甲硅烷基烯醇醚或甲硅烷基烯酮缩醛的环加成反应，然后使用三氟乙磺酸三苯醚1作为起始原料进行裂解。
• Studies on Anti-MRSA Parenteral Cephalosporins. III. Synthesis and Antibacterial Activity of 7.BETA.-[2-(5-Amino-1,2,4-thiadiazol-3-yl)-2(Z)-alkoxyiminoacetamido]-3-[(E)-2-(1-alkylimidazo[1,2-b]pyridazinium-6-yl)thiovinyl]-3-cephem-4-carboxylates and Related Compounds.
  作者：TOMOYASU ISHIKAWA、KEIJI KAMIYAMA、YUTAKA NAKAYAMA、YUJI IIZAWA、KENJI OKONOGI、AKIO MIYAKE

  DOI：10.7164/antibiotics.54.257

  日期：——

  In the course of our exploration for a novel cephalosporin derivative having excellent antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA), we modified the C-3 linked spacers of cephem derivatives bearing a l-methylimidazo[l, 2-b]pyridazinium-6-yl group at the C-3' position and 2-(5-amino-l, 2, 4-thiadiazol-3-yl)-2(Z)-cyclopentyloxyiminoacetyl group at the C-7 position. The optimal spacers were the (E)-2-vinyl and (E)-2-thiovinyl groups seen in 19a and 29aa, respectively. Their anti-MRSA activity was 16 to 32 times as potent as that of cefozopran (CZOP). Focusing on the (E)-2-vinyl and (E)-2-thiovinyl spacers, we further modified the alkoxyimino groups in the C-7 acyl moiety and the 1-alkylimidazo[l, 2-b]pyridazinium moieties at the C-3' position and investigated the structureactivity relationships (SAR) of the derivatives. Consequently, we selected 7β-[2-(5-aminol, 2, 4-thiadiazol-3-yl)-2(Z)-fluoromethoxyiminoacetamido]-3-[(E)-2-(l-methylimidazo[l, 2-b]pyridazinium-6-yl)thiovinyl]-3-cephem-4-carboxylate (29ca) as a new anti-MRSA parenteral cephalosporin candidate for further biological evaluation. The selected 29ca showed anti-MRSA activity comparable to that of vancomycin (VCM) both in vitro and in vivo, high affinity (IC50=2.7 μg/ml) for penicillin binding protein 2' (PBP2') of MRSA and potent activity against Gram-negative bacteria as well.

  在我们探索具有优异抗甲氧西林耐药金黄色葡萄球菌（MRSA）抗菌活性的新的头孢菌素衍生物的过程中，我们对具有l-甲基咪唑[1, 2-b]吡咯噻啉-6-基团的C-3链接间隔物进行了修改，其位于C-3'位置，以及具有2-(5-氨基-1, 2, 4-噻二唑-3-基)-2(Z)-环戊基氧基亚胺乙酰基团的C-7位置。最优间隔物是19a和29aa中的(E)-2-乙烯基和(E)-2-硫乙烯基，分别其抗MRSA活性是头孢佐芬（CZOP）活性的16到32倍。我们针对(E)-2-乙烯基和(E)-2-硫乙烯基间隔物，进一步修改了C-7酰基部分的烷氧亚胺基团和C-3'位置的1-烷基咪唑[1, 2-b]吡咯噻啉基团，并研究了这些衍生物的构效关系（SAR）。因此，我们选择了7β-[2-(5-氨基-1, 2, 4-噻二唑-3-基)-2(Z)-氟甲氧基亚胺乙酰氨基]-3-[(E)-2-(l-甲基咪唑[1, 2-b]吡咯噻啉-6-基)硫乙烯基]-3-头孢菌素-4-羧酸酯（29ca）作为新的抗MRSA注射用头孢菌素候选物进行进一步的生物评价。所选择的29ca在体外和体内的抗MRSA活性与万古霉素（VCM）相当，对MRSA的青霉素结合蛋白2'（PBP2'）具有高亲和力（IC50=2.7 μg/ml），并对革兰阴性细菌同样表现出强大的活性。
• CEPHALOSPORIN DERIVATIVE
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP0691343A1

  公开（公告）日：1996-01-10

  A cephalosporin derivative represented by general formula (I) or a salt thereof, wherein R¹ represents hydrogen, lower alkenyl, lower alkynyl, cycloalkyl, hydroxyl-protecting group, or (un)substituted lower alkyl; R² represents hydrogen, ester residue, or negative charge; R³ represents either (1) a group represented by general formula (a), wherein R⁴ and R⁵ represent each independently lower alkoxy or (un)substituted amino, or R⁴ and R⁵ may be combined together with the neighboring tetrahydropyridazine ring to form an (un)substituted fused 5- or 6-membered ring, or (2) a group represented by general formula (b) or (c), wherein R⁶ and R⁷ represent each independently hydrogen, halogen, amino, azido, carbamoyl, lower alkyl which may be substituted by amino, azido, carbamoyl or halogen, carbamoyl, or (un)substituted 5- or 6-membered heterocyclic group (provided the nitrogen atom of the heterocycle may be substituted to form a quaternary amine); X represents methine (-CH=) or nitrogen; and ring A represents a 4- to 5-membered nitrogenous heterocycle which may contain oxygen.

  由一般式(I)表示的头孢菌素衍生物或其盐，其中R¹代表氢、较低的烯基、较低的炔基、环烷基、羟基保护基团，或(未)取代的较低烷基；R²代表氢、酯残基或负电荷；R³表示(1)由一般式(a)表示的基团，其中R⁴和R⁵各自独立地代表较低的烷氧基或(未)取代的氨基，或R⁴和R⁵可以与相邻的四氢吡啶环结合在一起形成(未)取代的融合的5-或6-成员环，或(2)由一般式(b)或(c)表示的基团，其中R⁶和R⁷各自独立地代表氢、卤素、氨基、叠氮基、氨甲酰基、可能被氨基、叠氮基、氨甲酰基或卤素取代的较低烷基，氨甲酰基，或(未)取代的5-或6-成员杂环基团(假设杂环的氮原子可能被取代以形成季铵胺)；X代表亚甲基(-CH=)或氮；环A代表可能含氧的4-至5-成员氮杂环。
• Reactions of organocuprates with vinyl-triflates and related cephems: A novel approach to 3-substituted cephalosporins
  作者：Joydeep Kant、Chester Sapino、Stephen R. Baker

  DOI：10.1016/s0040-4039(00)97404-5

  日期：1990.1

  Vinyl-triflates and related 3-substituted cephems readily undergo addition-elimination reactions with a variety of organocuprates to form new carbon-carbon bonds. This chemistry presents a novel approach to the synthesis of 3-alkyl, 3-aryl, and 3-alkenylcephalosporins.

  乙烯基三氟甲磺酸酯和相关的3-取代的头孢很容易与各种有机铜化合物进行加成消除反应，以形成新的碳-碳键。该化学方法提供了一种合成3-烷基，3-芳基和3-烯基头孢菌素的新颖方法。
• Cephalosporin derivatives
  申请人：Pfizer Inc.

  公开号：US05578592A1

  公开（公告）日：1996-11-26

  Compounds of formula (I) or salts thereof: wherein R.sup.1 is hydrogen, methoxy or formamido; R.sup.2 is an acyl group; CO.sub.2 R.sup.3 is a carboxy group or a carboxylate anion, or R.sup.3 is a readily removable carboxy protecting group or a pharmaceutically acceptable salt-forming group or in vivo hydrolysable ester group; R.sup.4, R.sup.5, R.sup.6 and R.sup.7 independently represent hydrogen or a bond or a substituent group or may form a cyclic system. These compounds have antibacterial activity.

  式(I)的化合物或其盐：其中R.sup.1是氢，甲氧基或甲酰胺基；R.sup.2是酰基；CO.sub.2 R.sup.3是羧基或羧酸根离子，或R.sup.3是易于去除的羧基保护基或药用盐形成基或体内可水解的酯基；R.sup.4、R.sup.5、R.sup.6和R.sup.7独立地代表氢或键或取代基，或可形成环状系统。这些化合物具有抗菌活性。